Skip to main content
. 2016 May 27;7(32):52553–52574. doi: 10.18632/oncotarget.9651

Figure 3. Potential treatment approaches targeting FRα.

Figure 3

1) Folate drug-conjugates: chemotherapeutic agents, such as vintafolide, have been conjugated to folate for FRα targeting. 2) Vaccines targeting FRα: autologous dendritic cells engineered with FRα mRNA commence an anti-FRα immune response, mediated by T-cells. 3) Chimeric antigen receptor (CAR) T cells: CAR T cells recognizing FRα trigger tumor cell killing. 4) Monoclonal antibodies (direct effects): Specific recognition of FRα lead to inhibition of downstream signaling events that cause tumor cell death. 5) Monoclonal antibodies (immune effector cell engagement): antibodies link FRα-expressing tumor cells with immune effector cells that bear Fc receptors, potentiate effector cell activation and target-neutralizing functions by engendering antibody-dependent effector cell-mediated cytotoxicity (ADCC), phagocytosis (ADCP) or 6) complement-dependent cytotoxicity (CDC) activation.